Login to Your Account



ADA 2011

MacroGenics is Optimistic on Posthoc Analyses of Protégé

By Anette Breindl


Wednesday, June 29, 2011
Among the data to be presented at the American Diabetes Association's annual meeting this week were additional analyses of Rockville, Md.-based MacroGenics Inc.'s anti-CD3 antibody teplizumab.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription